A trial evaluated the short-term oncologic efficacy of cooled focal therapy ablation using the ProFocal device in men with localized, intermediate-risk prostate cancer.

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Share on Pinterest A new drug combo therapy significantly improved overall survival rates in males with locally advanced prostate cancer. Maskot/Getty Images A drug combination already used in ...

The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.

Please provide your email address to receive an email when new articles are posted on . Cardiovascular risk assessments used in the general population did not accurately predict risk among men with ...